-
PPMD 2024: Conference keynote address recalls 30 years of advocacy
Parent Project Muscular Dystrophy (PPMD) held its first conference in 1994, in Orlando, Florida. A […]
-
When did I stop being a fun mom for my children?
“I didn’t think you’d jump with us,” said my daughter Mary, 9, breathing heavily as […]
-
PPMD 2024: 30 years of ‘progress, community, and resilience’
The Parent Project Muscular Dystrophy (PPMD) 30th annual conference kicks off today, offering families affected […]
-
Capricor Therapeutics Announces Positive Skeletal Muscle and Cardiac Function Data from HOPE-2 OLE Study Data of Deramiocel (CAP-1002)
Capricor Therapeutics today announced additional positive 3-year safety and efficacy results from the company’s ongoing […]
-
Upcoming Capricor, FDA meeting to focus on DMD treatment deramiocel
Capricor Therapeutics will soon meet with the U.S. Food and Drug Administration (FDA) to discuss […]
-
Study of LGMD2i therapy BBP-418 exceeds interim analysis enrollment
A Phase 3 trial testing an experimental therapy for limb-girdle muscular dystrophy type 2i (LGMD2i) has […]
-
Mattress shopping really makes me want to take a nap
Last week, my wife, Wendy, and I finally got around to starting the process of […]
-
PPMD Convenes Leading Experts to Discuss Topics in Becker Care Ahead of 30th Annual Conference
Leading into PPMD’s 30th Annual Conference, PPMD is excited to host a professional meeting focusing […]
-
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse […]
-
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be […]
